| abstract |
REFERS TO COMPOUNDS DERIVED FROM PYRIDAZINONE OF FORMULA (I) WHERE R1 IS Ar OR Het, WHERE Ar IS PHENYL, NAPHTHYL OR BIPHENYL; Het IS A MONO-, DI- OR TRICYCLIC HETEROCYCLE; R2 IS A 6-MEMBER HETEROCICLE OPTIONALLY SUBSTITUTED WITH NO2, CN, AMONG OTHERS; R3 IS H OR A, WHERE A IS ALKYL (C1-C10) OPTIONALLY SUBSTITUTED WITH F, OR CYCLOALKYL (C3-C7); R4 AND R4 'ARE EACH H, HALOGEN, A, OR3, CN, AMONG OTHERS. PREFERRED COMPOUNDS ARE: 2- [3- (5-METHYLPYRIMIDIN-2-IL) -BENZYL] -6- (3,4,5-TRIFLUOROPHENYL) -2H-PYRIDAZIN-3-ONA, 6- (3,5-DIFLUOROPHENIL ) -2- [3- (5-METHYL-PYRIMIDIN-2-IL) -BENZYL] -2H-PYRIDAZIN-3-ONA, 2- [3- (4-METHYL-PYRIMIDIN-2-IL) -BENZYL] - 6- (3,4,5-TRIFLUORO-PHENYL) -2H-PYRIDAZIN-3-ONA, AMONG OTHERS. IT ALSO REFERS TO A PREPARATION PROCEDURE AND A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE INHIBITORS OF TYROSINE KINASES, ESPECIALLY OF MET-KINASE, BEING USEFUL IN THE TREATMENT OF SOLID TUMOR COMING FROM MONOCYTIC LEUKEMIA, ADENOCARCINOMA OF THE LUNG, CANCER OF PANCREAS, GIOBLOMASTOMAS, CARONCREAS |